Liver Cancer - Karger Publishers
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
10 | 1 | 21 Liver Cancer
F21507
Official Journal of the Asia-Pacific Primary Liver Cancer Expert Association (APPLE)
Affiliated with the Eastern and Western Association on Liver Tumors (EWALT)
Liver Cancer
Official Journal of Editor-in-Chief
Masatoshi Kudo – Kindai University, Osaka, Japan
Associate Editors
Pei-Jer Chen – National Taiwan University Hospital, Taipei, Taiwan
Ann-Lii Cheng – National Taiwan University Hospital, Taipei, Taiwan
APPLE Editorial Representatives Jia Fan – Fudan University, Shanghai, China
M. Kudo, Osaka Kwang-Hyub Han – Yonsei University College of Medicine, Seoul, Korea
K.-H. Han, Seoul Namiki Izumi – Musashino Red Cross Hospital, Tokyo, Japan
S.-L. Ye, Shanghai Norihiro Kokudo – National Center for Global Health and Medicine, Tokyo, Japan
Jeong Min Lee – Seoul National University College of Medicine, Seoul, Korea
Affiliated with Riccardo Lencioni – Pisa University School of Medicine, Pisa, Italy
Jens Ricke – Ludwig-Maximilians-Universität München, Munich, Germany
Lewis R. Roberts – Mayo Clinic, Rochester, MN, USA
Michiie Sakamoto – Keio University, Tokyo, Japan
Augusto Villanueva – Icahn School of Medicine at Mount Sinai, New York, NY, USA
Sheng-Long Ye – Fudan University, Shanghai, China
Andrew X. Zhu – Massachusetts General Hospital Cancer Center, Boston, MA, USA
Editorial Board Members
Jacques Belghiti – Beaujon Hospital, Clichy, France
See Ching Chan – Queen Mary Hospital University, Hong Kong, China
Pierce Chow – Duke-NUS Graduate Medical School, Singapore, Singapore
Laura Crocetti – University of Pisa, Pisa, Italy
Alessandro Cucchetti – University of Bologna, Bologna, Italy
Richard S. Finn – University of California at Los Angeles, Santa Monica, CA, USA
Francesca Fornari – University of Bologna, Bologna, Italy
Junji Furuse – Kyorin University, Tokyo, Japan
Liana Gheorghe – Fundeni Clinical Institute, Bucharest, Romania
Kiyoshi Hasegawa – The University of Tokyo, Tokyo, Japan
Etsuro Hatano – Kyoto University, Kyoto, Japan
Massimo Iavarone – University of Milan, Milan, Italy
Masafumi Ikeda – National Cancer Center Hospital East, Kashiwa, Japan
Yasuharu Imai – Ikeda Municipal Hospital, Osaka, Japan
Masa Kanematsu – Gifu University Hospital, Gifu, Japan
Xiao-Jie Lu – Nanjing Medical University, Nanjing, China
(Continued on next page)
Printed in Germany on acid-free and non-aging paper
(ISO 9706) by Stückle Druck, Ettenheim
(Continued)
Irene Oi-lin Ng – The University of Hong Kong, Hong Kong, China
Naoshi Nishida – Kindai University, Osaka, Japan
Kazuhiro Nouso – Okayama University, Okayama, Japan
Fabio Piscaglia – University of Bologna, Bologna, Italy
Toshiharu Sakurai – Kindai University, Osaka, Japan
Peter Schemmer – Medical University of Graz, Graz, Austria
Jinsil Seong – Yonsei University, Seoul, Korea
Wolfgang Sieghart – Medical University of Vienna, Vienna, Austria
Ryosuke Tateishi – The University of Tokyo, Tokyo, Japan
Guido Torzilli – Humanitas University, Milan, Italy
Kaoru Tsuchiya – Musashino Red Cross Hospital, Tokyo, Japan
Kazuomi Ueshima – Kindai University, Osaka, Japan
Maria Varela – Hospital Universitario Central de Asturias, Oviedo, Spain
Jean Nicolas Vauthey – University of Texas, Houston, TX, USA
Chris Verslype – University of Leuven, Leuven, Belgium
Arndt Weinmann – Johannes Gutenberg University, Mainz, Germany
Tatsuya Yamashita – Kanazawa University Hospital, Kanazawa, Japan
© 2021 S. Karger AG, Basel
www.karger.com
karger@karger.com
Journal Information
Aims and Scope
Liver cancer has a very high prevalence among cancers in general and is one of the most
common causes of death worldwide. Based on these facts, the journal Liver Cancer serves
the growing need to better understand the causes, mechanisms and therapy of the malig-
nancy. It provides the international community of researchers and clinicians with a platform
for their research results, focusing on molecular carcinogenesis, prevention, surveillance,
Guidelines for Authors diagnosis and treatment, including molecular targeted therapy, of the disease. Liver Cancer
We strongly encourage authors to read
the Guidelines for Authors at
publishes clinical and translational research related to the field of liver cancer in both hu-
www.karger.com/lic_guidelines prior to mans and experimental models in the form of original and review articles.
submitting an article.
Journal Contact
For questions or comments, please contact
the persons responsible who can be found at
https://www.karger.com/Journal/Contact/255487.
ISSN Print Edition: 2235–1795 Disclaimer: The statements, opinions and data con-
ISSN Online Edition: 1664–5553 tained in this publication are solely those of the indi-
vidual authors and contributors and not of the pub-
Journal Homepage: www.karger.com/lic lisher and the editor(s). The appearance of advertise-
Bibliographic Indices: This journal is regularly listed ments in the journal is not a warranty, endorsement,
in bibliographic services including PubMed. or approval of the products or services advertised or
of their effectiveness, quality or safety. The publisher
Publication Data: Liver Cancer is published 6 times and the editor(s) disclaim responsibility for any injury
a year. Volume 10 with 6 issues appears in 2021. to persons or property resulting from any ideas,
methods, instructions or products referred to in the
Copyright: © 2021 S. Karger AG, Basel (Switzerland). content or advertisements.
All rights reserved. No part of this publication may be
translated into other languages, reproduced or uti-
lized in any form or by any means, electronic or me-
chanical, including photocopying, recording, micro-
copying, or by any information storage and retrieval
system, without permission in writing from the pub-
lisher.
© 2021 S. Karger AG, Basel
www.karger.com
karger@karger.com
Vol. 10, No. 1, 2021
Contents
Editorial
1 Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable
Hepatocellular Carcinoma
Kudo, M. (Osaka)
Meta-Analysis
10 Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in
Hepatocellular Carcinoma
Surov, A.; Pech, M.; Omari, J.; Fischbach, F.; Damm, R.; Fischbach, K.; Powerski, M.; Relja, B.
(Magdeburg); Wienke, A. (Halle)
Original Papers
25 Laparoscopic Liver Resection versus Percutaneous Radiofrequency Ablation for
Small Single Nodular Hepatocellular Carcinoma: Comparison of Treatment Outcomes
Lee, D.H. (Seoul); Kim, J.W. (Chosun); Lee, J.M. (Seoul); Kim, J.M.; Lee, M.W.; Rhim, H. (Samsung);
Hur, Y.H. (Chonnam); Suh, K.-S. (Seoul)
38 Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First
Transarterial Chemoembolization in Hepatocellular Carcinoma
Chen, M.; Cao, J.; Hu, J.; Topatana, W.; Li, S.; Juengpanich, S. (Hangzhou); Lin, J. (Quzhou); Tong, C.
(Shaoxing); Shen, J.; Zhang, B. (Hangzhou); Wu, J. (New York, NY); Pocha, C. (Sioux Falls, SD); Kudo, M.
(Osaka); Amedei, A. (Florence); Trevisani, F. (Bologna); Sung, P.S. (Seoul); Zaydfudim, V.M.
(Charlottesville, VA); Kanda, T. (Tokyo); Cai, X. (Hangzhou); AME Hepatocellular Carcinoma
Collaborative Group
52 Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma
in a Real-World Practice in Korea
Goh, M.J.; Oh, J.H.; Park, Y.; Kim, J.; Kang, W.; Sinn, D.H.; Gwak, G.-Y.; Paik, Y.-H.; Choi, M.S.; Lee, J.H.;
Koh, K.C.; Paik, S.W. (Seoul)
63 Feasibility and Techniques of Securing 3D-Safety Margin in Superselective
Transarterial Chemoembolization to Improve Local Tumor Control for Small
Hepatocellular Carcinoma: An Intend-to-Treat Analysis
Charoenvisal, C. (Kashihara/Bangkok); Tanaka, T.; Nishiofuku, H. (Kashihara); Anai, H. (Nara); Sato, T.;
Matsumoto, T.; Marugami, N.; Kichikawa, K. (Kashihara)
72 Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes
for Small Hepatocellular Carcinoma: A Randomized Clinical Trial
Park, S.-J.; Cho, E.J.; Lee, J.-H.; Yu, S.J.; Kim, Y.J.; Yoon, J.-H.; Kang, H.-J.; Yoon, J.H.; Lee, D.H.; Kim, S.H.;
Lee, J.Y.; Lee, J.M. (Seoul)
Society News
82 APPLE News
Cover illustration
© 123rf.com
© 2021 S. Karger AG, Basel
Access to full text and tables of contents,
including tentative ones for forthcoming issues:
www.karger.com/lic
F21502
Doing everything
we can for patients
who are waiting
C
M
Y
M AbbVie is a research-driven global
Y
biopharmaceutical company headquartered
Y
in the United States.
MY
K
AbbVie GK
3-1-21 Shibaura, Minato-ku
Tokyo 108-0023, Japan
https://www.abbvie.co.jp/
F21501An international platform for key opinions and research
Editors
Jing-Yuan Fang,
Shanghai
Peter Malfertheiner,
Munich
Gastrointestinal Tumors is an international, peer-reviewed journal that Selected contributions
brings together the leading opinions in all fields related to gastrointes- • Mortality and Survival after Surgical Treatment of Colorectal Cancer in
tinal cancer research. Ranging from the identification of new therapeu- Patients Aged over 80 Years: Mäkelä, J.T.; Klintrup, K.H.; Rautio, T.T. (Oulu)
tic targets to epidemiology, disease prevention, treatment and patient • Diffuse-Type Hepatoma: A Grave Prognostic Marker: Siriwardana, R.C.;
management, the journal provides a platform for the dissemination of Liyanage, C.A.H.; Gunetilleke, B.; Niriella, M.A.; de Silva, J.; Dassanayake, A.S.;
Jayatunge, S.P. (Ragama)
key opinions and research from thought leaders in the field. By publish-
• Impact of Three-Dimensional Surgical Simulation on Pancreatic Surgery:
ing timely reviews and original papers covering the latest develop- Miyamoto, R.; Oshiro, Y.; Nakayama, K.; Ohkohchi, N. (Tsukuba)
ments, the journal will help readers gain insight into the evolving body • Waiting Time following Neoadjuvant Chemoradiotherapy for Rectal
of research across the relevant disciplines. Cancer: Does It Really Matter: Plastiras, A.; Sideris, M.; Gaya, A.; Haji, A.;
Nunoo-Mensah, J.; Haq, A.; Papagrigoriadis, S. (London)
• Dietary and Lifestyle Factors Associated with Colorectal Cancer Risk and
Interactions with Microbiota: Fiber, Red or Processed Meat and Alcoholic
Drinks: Tuan, J.; Chen, Y.-X. (Shanghai)
• Etiology and Prevention of Gastric Cancer: Cheng, X.J.; Lin, J.C.; Tu, S.P.
(Shanghai)
• Prevention of Hepatocellular Carcinoma: Schütte, K. (Osnabrück);
Balbisi, F.; Malfertheiner, P. (Magdeburg)
• A Recent Advance in Image-Guided Locoregional Therapy for
Hepatocellular Carcinoma: Shi, Y.; Zhai, B. (Shanghai)
Gastrointestinal Tumors
Founded: 2014
Category: Clinical Research
Fields of Interest: Gastroenterology, Oncology
Listed in bibliographic services, including:
PubMed/PubMed Central, Google Scholar, Embase
2019: Volume 6
4 issues per volume
Language: English
KF19049
ISSN 2296–3774
e-ISSN 2296–3766 More information at w w w. karger.com/gatF21503
Progress in Tumor Research
Read it online: Overviews of key areas of tumor research
www.karger.com/ptr
Series Editors Progress in Tumor Research
Editors: R.A. Stahel, S. Peters
Vol. 44
Progress in Tumor Research
Editors: R.A. Stahel, S. Peters
Vol. 43
Progress in Tumor Research
(formerly Progress in Experimental Tumor Research)
Editors: R.A. Stahel, S. Peters
Progress in Tumor Research
(formerly Progress in Experimental Tumor Research)
Editors: R.A. Stahel, S. Peters
Vol. 42 Vol. 41
R.A. Stahel, Zurich Advances in Tumors in Adolescents Immuno-Oncology Successes and
Radiation Therapy and Young Adults Limitations of Targeted
S. Peters, Lausanne Editors
Editors
O. Michielin Cancer Therapy
Editors
D.P. Stark G. Coukos
M. Guckenberger Editors
S.E. Combs G. Vassal
S. Peters
D. Zips R.A. Stahel
All cancer, female, 15–39 years
750
600
Incidence (per million)
450
300
150
East North
South and West UK
0
1991 1994 1997 2000 2003 2006
Year
Endorsed by
SIOP
SIOP Europe
the European Society for Paediatric Oncology
Progress in Tumor Vol. 44: Advances in Vol. 43: Tumors in Vol. 42: Immuno-Oncology Vol. 41: Successes and
Research Radiation Therapy Adolescents and Editors: Michielin, O.; Coukos, G. Limitations of Targeted
Founded: 1960 Editors: Guckenberger, M. (Zurich); Young Adults (Lausanne) Cancer Therapy
Field of Interest: Oncology Combs, S.E. (Munich); Zip, D. Editors: Stark, D.P. (Leeds); Vassal, G. VI + 140 p., 8 fig., 5 in color, Editors: Peters, S. (Lausanne);
(Tübingen) (Villejuif) 11 tab., 2015 Stahel, R.A. (Zurich)
Listed in bibliographic services, CHF 198.00 / EUR 185.00 / USD 233.00
X + 134 p., 24 fi g., 20 in color, X + 146 p., 15 fig., 9 in color, VI + 118 p., 12 fig., 6 in color,
including: PubMed/MEDLINE, (hardcover or online*)
4 tab., 2018 19 tab., 2016 19 tab., 2014
Google Scholar, Scopus CHF 238.00 / EUR 222.00 /
CHF 160.00 / EUR 150.00 / USD 188.00 CHF 198.00 / EUR 185.00 / USD 233.00 CHF 163.00 / EUR 152.00 / USD 192.00
ISSN 2296–1895 (hardcover or online*) (hardcover or online*) USD 288.00 (online**) (hardcover or online*)
e-ISSN 2296–1887 CHF 192.00 / EUR 180.00 / USD 226.00 CHF 238.00 / EUR 222.00 / ISBN 978–3–318–05589–4 CHF 196.00 / EUR 182.00 / USD 230.00
(online**) USD 288.00 (online**) e-ISBN 978–3–318–05590–0 (online**)
ISBN 978–3–318–06361–5 ISBN 978–3–318–05911–3 ISBN 978–3–318–02541–5
e-ISBN 978–3–318–06362–2 e-ISBN 978–3–318–05912–0 e-ISBN 978–3–318–02542–2
KI 19031
*online prices for personal customer **online prices for institutional purchase
Prices subject to change, VAT not included. EUR price for eurozone countries, USD price for USA and Latin America onlyF21506
EA21029Nexavar® 200mg Stivarga ® 40mg
Sorafenib Tosilate (anticancer agent / kinase inhibitor) Regorafenib Hydrate (anticancer agent / kinase inhibitor)
Deleterious / Prescription drug＊ Deleterious / Prescription drug＊
Listing in the National Health Insurance drug price list Listing in the National Health Insurance drug price list
＊Caution : Use under prescription from a physician, etc. ＊Caution : Use under prescription from a physician, etc.
Please refer to the package insert for the indications, dosage and administration,
and precautions including box warnings and contraindications
Distributed and marketed by
F21504
PP-NEX-JP-0373-20-11 （2019/12）FREE
ACCESS
Topic Article Package:
COVID-19
karger.com/
IA21001
COVIDYou can also read
